Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy

Cited by (772)

Items 601–700 of 772

1. ACCF/AHA Practice Guideline
   Clyde W. Yancy, Mariell L Jessup, Biykem Bozkurt, Javed Butler, Mark H. Drazner, Gregg C. Fonarow, Stephen A. Geraci, Tamara B. Horwich, James L. Januzzi, Maryl R. Johnson et al. · 2013
2. STATINS IN PREVENTION OF ISCHEMIC STROKE
   Andrey V. Susekov, A. B. Blohin, З. Г. Лугинова, E. J. Soloveva, N. V. Maltseva, O. E. Tarasova, V. V. Kuharchuk · 2013 · Rational Pharmacotherapy in Cardiology
3. Risikofaktormanagement bei KHK
   Ephraim B. Winzer, Gerhard C Schuler · 2013 · CardioVasc
4. Lipid Lowering in Coronary Artery Disease
   Kausik Kumar Ray, Christopher Paul Cannon · 2012 · Elsevier eBooks
5. Angiography and Interventions Association Task Force on Practice Guidelines and the Society for Cardiovascular Summary : A Report of the American College of Cardiology Foundation/American Heart 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive
   Daniel N. Moussa, Brahmajee K. Nallamothu, Henry H. Ting, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, John A. Bittl, Charles E. Chambers et al. · 2012
6. In Patients with Cardiovascular Disease, Do Statins Alone, or in Combination with Other Medications Improve Mortality?
   Bjoern Dominik Suckow, Philip P. Goodney · 2017 · Difficult decisions in surgery: an evidence-based approach
7. Atheroembolism
   Roger F.J. Shepherd · 2012 · Elsevier eBooks
8. How Cox models react to a study-specific confounder in a patient-level pooled dataset: random effects better cope with an imbalanced covariate across trials unless baseline hazards differ
   Thomas McAndrew, Björn Redfors, Aaron Crowley, Yiran Zhang, Shmuel Chen, Mordechai Golomb, Maria C. Alu, Dominic P. Francese, Ori Ben‐Yehuda, Akiko Maehara et al. · 2019 · Journal of Applied Statistics
9. The usual dosage regimen of statins and adherence to target LDL-cholesterol levels by Czech patients in the secondary prevention of coronary heart disease
   Otto Mayer, Jaroslav Šimon, Jan Bruthans, Markéta Galovcová, Jana Hrbková, Jiří Bělohoubek · 2009 · Cor et Vasa
10. New approach for the rehabilitation of patients with chronic heart failure associated with type 2 diabetes
    Синькова Маргарита Николаевна, Исаков Леонид Константинович, М. А. Синьков, Ekaterina Yu. Plotnikova, Е. Н. Гуляева · 2020 · Meditsinskiy sovet = Medical Council
11. ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
    Glenn N. Levine, Eric Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg et al. · 2011
12. In patients at high risk, the lower the low density cholesterol (c-LDL), the better: How low and which is its grade of recommendation and evidence level?
    Alonso Merchán · 2008 · Revista Colombiana de Cardiología
13. LDL Targeted Therapies
    Raul Dias Santos, Khurram Nasir, Roger Scott Blumenthal · 2010 · Humana Press eBooks
14. New approaches to reduce recurrent PCI: to angioplasty and beyond!
    Pierre François Sabouret, Stéphane Manzo‐Silberman, Mirvat A. Alasnag, M. Fysekidis, Martha Gulati, Giuseppe Galati, Luigi Spadafora, Maciej Banach, Giuseppe Biondi‐Zoccai, Deepak L. Bhatt · 2023 · European Heart Journal Open
15. The Gulf Achievement of Cholesterol Targets in Out-Patients Study (GULF ACTION): Design, Rationale, and Preliminary Results
    Hanan B. Albackr, Khalid Al Waili, Wael A. Almahmeed, Mohammad Al Jarallah, Mohammad Amin, Khalid Al‐Rasadi, Mohammed Ali Batais, Turky H. Almigbal, Ali A. Youssef, Mohammad A. AlGhamdi et al. · 2023 · Current Vascular Pharmacology
16. Research Progress on Hyperlipidemia
    成消 李 · 2024 · Advances in Clinical Medicine
17. High Dose Statin as Upstream Therapy and the Frequency of Slow-Flow Phenomenon in Patients Undergoing Primary PCI or Immediate Invasive Therapy
    Anwar Jamal Khan, Somera Naz · 2024 · Journal of Health and Rehabilitation Research
18. Assessment of post-myocardial infarction lipid levels and management: Results from a tertiary care hospital of Pakistan
    Rubina Rauf, Muhammad Ismail Soomro, Muhamman Nauman Khan, Mukesh Kumar, Najia Aslam Soomro, Khawar Abbas Kazmi · 2024 · World Journal of Cardiology
19. Rationale for Increasing Doses of Statins in Everyday Clinical Practice
    Andrey V. Susekov · 2024 · Kardiologiia
20. Safety and Effectiveness of Pravastatin in Korean Patients with Dyslipidemia Based on the Cardiovascular Risk Classification: Pooled Analysis of Four Observational Studies
    In‐Kyung Jeong, Hyuk‐Sang Kwon, Dae Jung Kim, Sin Gon Kim · 2025 · Endocrinology and Metabolism
21. Clinical inquiries. What does the evidence tell us about treating very-high-risk patients to an LDL <70 mg/dL?
    Carrie Nelson, Kristin Hitchcock, James A Bohlen, Wail Malaty · 2009 · PubMed
22. The changes of secondary prevention practice in Czech post-stroke patients between 2007 and 2012/13
    Jiří Vaněk, Otto Mayer, Peter Wohlfahrt, Lenka Kielbergerová, Alena Krajčoviechová, Jan Bruthans, Renata Cífková · 2016 · Cor et Vasa
23. Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
    Satoshi Yamaguchi, Kageyuki Oba, Moritake Higa, Osamu Arasaki, Michio Shimabukuro · 2020 · Journal of Clinical Medicine
24. Evaluation of Hypolipidemic and TNF-α Lowering Effect of Ficus Religiosa in Dyslipidemic Wistar Rats
    Rajendra Nath · 2019 · Current Research in Diabetes & Obesity Journal
25. Atorvastatin-Induced Myalgia in Iranian Patients: A Hospital-Based Study to Determine the Prevalence and Associated Risk Factors
    Farzaneh Dastan, Jamshid Salamzadeh, Ali Saffaei, Yasaman Nabavi, Mohammad Abbasinazari · 2021 · Journal of Pharmaceutical Care
26. The effect of switching from statin-monotherapy to statin/ezetimibe combination therapy on lipid profiles in patients with type 2 diabetes and dyslipidemia: a multicenter open-label study (EUCLID)
    Mitsuhide Takeshita, Atsushi Tanaka, Atsushi Kawaguchi, Keiko Sato, Shigeru Toyoda, Teruo Inoue, Koichi Node, On behalf of the EUCLID Study Investigators · 2020 · Vascular Failure
27. Hyperlipidämie
    Aniela Angelow, Jean‐François Chenot · 2021 · Elsevier eBooks
28. Efficacy of high- versus moderate-dose statin therapy on lower extremity artery disease after revascularization
    Ayhan Küp, Batur Gonenc Kanar, Abdülkadir Uslu, Regayi̇p Zehi̇r, Dursun Akaslan, Alper Kepez · 2022 · Marmara medical journal
29. Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention
    Morteza Chehrevar, Reza Golchin Vafa, Mohammadhossein Rahmani, Mohammadjavad Mehdizadeh Parizi, Amin Ahmadi, Bardia Zamiri, Reza Heydarzadeh, Mohammad Montaseri, Seyed Ali Hosseini, Javad Kojuri · 2022 · Interventional Cardiology Reviews Research Resources
30. Tratamiento posterior a un ataque cerebrovascular con estatinas y metas de colesterol de baja densidad
    Valentina Sierra, Eder A. Moreno-Vargas, Sebastián Escandón-Castillo, Diego Rincón-García, Andrea Silva-Duran, Hernán Bayona · 2023 · Acta neurológica colombiana
31. Secondary prevention for coronary heart disease in the United Kingdom, low-density lipoprotein cholesterol goals and statin switching-an expression of concern
    Kausik Kumar Ray, Peter M. Schofield · 2007 · International Journal of Clinical Practice
32. Management of Diabetic Dyslipidaemia
    D. J. Betteridge · 2007 · Springer eBooks
33. Shifting to new targets in pharmacological prevention of cardiovascular diseases
    Jan Åke Nilsson, Petri T. Kovanen · 2009 · Current Opinion in Lipidology
34. Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
    Padma Kaul · 2006 · European Heart Journal
35. Traitement de l'infarctus du myocarde avec sus-décalage du segment ST
    Xavier Armoiry, X. Dode, Eric Bonnefoy‐Cudraz, G. Aulagner, François Gimenez, Éric François · 2008 · Elsevier eBooks
36. Obstacles to Optimal Lipid-Lowering Therapy ― Any Solution? ―
    Yu Kataoka · 2018 · Circulation Journal
37. Cost/effectiveness analysis of atorvastatin in patients with acute coronary syndromes
    Simona Cammarota, Enrica Menditto, Daria Putignano, Anna Citarella · 2010 · Farmeconomia Health economics and therapeutic pathways
38. Secondary hyperlipidaemia
    2007 · CRC Press eBooks
39. Identification of secondary prevention patients eligible for PCSK9 inhibitors therapy according to the routine clinical practice in Spain
    Juan Cosı́n-Sales, Eduard Sidelnikov, Santiago Villamayor, Miriam Fernández, Sandra Merino-Montero, Alberto Zamora · 2022 · Research Square
40. Saturated Fat Restriction for Cardiovascular Disease Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Satoru Yamada, Tomomi Shirai, Sakiko Inaba, Gaku Inoue, Minami Torigoe, Naoto Fukuyama · 2024 · Research Square
41. Cholesterol Management and Risk Reduction – Current Guidelines and Barriers to Goal Attainment
    G. Holt, P. Wong, Touch Briefings Medical Writer · 2008 · Asia Pacific Cardiology
42. Infarto agudo del miocardio en centros de diagnóstico integral. Municipio San Francisco. Zulia. Venezuela. 2007
    Luis Enrique Moreno Peña, Idalia Teresita Hernández Hervís, Raúl Moreno Peña, Gladys García Peñate, Rudy Saél González Mendoza · 2011 · Revista Médica Electrónica
43. Dyslipidemia and Its Management in Type 2 Diabetes
    D. J. Betteridge · 2014 · Wiley eBooks
44. Auf der Suche nach der richtigen Therapie
    Thomas Hucko, K. Graf · 2010 · Der Kardiologe
45. The cost of new therapies in cardiovascular care. Time for hope or despair for developing countries
    Abdallah Fandi Yousef Omeish · 2007 · Saudi Medical Journal
46. Effect of external counterpulsation on coronary collateral artery growth and myocardial blood flow in patients with stable coronary artery disease
    Nikolaos Pagonas · 2011 · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver
47. Integrated Primary Prevention of Cardiovascular Disease
    Huy Tran, Olabode Oladeinde, Nguyen Hai Thuy, Huynh Van Minh, Dao Duy An, Dat Nguyen Tran, Thach N Nguyen, Adolphus Anekwe, Matthew J. Sorrentino · 2007 · Wiley eBooks
48. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL
    Margrit Schwarz, Jae Bum Kim · 2011 · Wiley eBooks
49. En pacientes de alto riesgo, mientras más bajo el colesterol de baja densidad (c-LDL), mejor: ¿Qué tan bajo y cuál es su grado de recomendación y nivel de evidencia?
    Alonso Merchán · 2008 · DOAJ (DOAJ: Directory of Open Access Journals)
50. On-Clopidogrel Platelet Reactivity
    Stephen D. Wiviott, Willibald Hochholzer · 2011 · Journal of the American College of Cardiology
51. Overview of Evidence Supporting the Treatment of Hyperlipidemia
    Brian V Reamy · 2008 · Springer eBooks
52. Medical angioplasty - Hope and expectations: An optimistic overview
    MohammedF Abdul-Mohsen · 2011 · Journal of Family and Community Medicine
53. Statin therapy for secondary prevention of coronary heart disease: an update
    Kausik Kumar Ray, Lesley A Everett · 2008 · Primary Care Cardiovascular Journal (PCCJ)
54. New options for therapeutic management of patients with cardiovascular disease. A closer look at clinical trials with telmisartan
    Massimo Volpe · 2009 · Hot Topics in Hypertension
55. A Call for Development of Comprehensive Therapy for Dyslipidemia
    Niteen Vijay Deshpande, Harshawardhan M. Mardikar, Dhananjay Deo · 2007 · Journal of the American College of Cardiology
56. The Use of Combination Lipid Therapy in a County Health System
    Margaret Youngmi Pio, Erin Marie Piszczor, Marissa Escobar Quinones, Steven Michael Boatright, Diem Hong Chow, Jeffrey Lynn Hulstein, Elizabeth Moss, Annie Chathanatt Mathew, Nitin Budhwar · 2012 · Journal of Pharmacy Technology
57. Statin therapy to prevent stroke in the elderly
    Richard A. Bernstein · 2007 · Current Cardiovascular Risk Reports
58. How aggressively should cholesterol targets be pursued?
    Anthony S. Wierzbicki · 2007 · British Journal of Hospital Medicine
59. Cholesterol lowering to prevent stroke: Who, when, and how?
    Richard A. Bernstein · 2006 · Current Treatment Options in Neurology
60. Cholestérol et sujets âgés
    P. Friocourt · 2007 · NPG. Neurologie, psychiatrie, gériatrie/NPG
61. The ankle brachial index independently predicted all-cause mortality in high-risk patients with peripheral arterial disease
    BMJ Publishing Group Ltd · 2007 · BMJ Evidence-Based Medicine
62. Implementing the NICE guideline for secondary prevention of MI
    Jane S. Skinner · 2008 · Primary Care Cardiovascular Journal (PCCJ)
63. Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?
    Stephen James Nicholls, Srinivasa R Kalidindi, Steven E. Nissen · 2007 · Current Cardiovascular Risk Reports
64. New Perspectives on the Management of Type 2 Diabetes
    Anthony H Barnett, G. A. Hitman, Eugene Hughes, Kamlesh K. Khunti · 2008 · The British Journal of Diabetes
65. Lipid reduction in acute coronary syndrome: How much, when, and how?
    Miriam S. Jacob, Leslie Cho · 2009 · Current Cardiology Reports
66. Cumplimiento de las Recomendaciones de la Guía SEH/SEC 2007 en Población Hipertensa en un Centro de salud
    Ignacio Manuel Sánchez Barrancos, Pedro Domínguez Sánchez-Migallón, Domingo Zamora Martín, Antonio Iglesias Fernández, Rafael García García, Francisco Alhambra García Cervigón, A Moral, Carmen Martínez Gallardo, Antonio del Valle Cuerva · 2009 · Revista Clínica de Medicina de Familia
67. Very-low-strength evidence suggests that combining ezetimibe or fibrate with statins is no more effective than high-dose statin monotherapy for reducing all-cause mortality
    Alexander Tenenbaum, Enrique Z. Fisman · 2010 · BMJ Evidence-Based Medicine
68. Keeping Our Eyes on the Prize: Low Density Lipoprotein Cholesterol
    James A. de Lemos, Amit Khera · 2009 · The American Journal of Cardiology
69. Putting the benefits of percutaneous coronary revascularization into perspective: From trials to guidelines
    Kamal H. Sharma, Mark Jeffrey Eisenberg · 2008 · Current Cardiology Reports
70. LDL-cholesterol : lower is (truly) better
    Patrice Darmon · 2011 · Médecine des Maladies Métaboliques
71. Infiammazione e lipidi nella patologia coronarica. Fattori di rischio, cause scatenanti o target terapeutici?
    Pasquale Perrone Filardi, Milena Cecere, Gianluigi Savarese, Carmen D’Amore, Antonio Parente, Sirio Conte, Gloria Vassilikì Coutsoumbas · 2010 · Giornale italiano di cardiologia
72. Clinical trials of lipid-modifying agents:design considerations
    Louise J. Bowman, Richard Haynes, Jane Armitage · 2011 · Clinical Lipidology
73. Review: high dose statins reduce risk of non-fatal cardiovascular events more than standard dose statins
    Laura Kristin Newby · 2007 · BMJ Evidence-Based Medicine
74. C-reactive protein prior to percutaneous coronary intervention: Do we still need to check the lipid panel?
    Michael Joseph Lipinski, Ron Waksman · 2014 · Cardiovascular revascularization medicine
75. ¿Es necesario reducir aún más el colesterol-LDL en prevención secundaria?
    Pascual Solanas · 2014 · FMC - Formación Médica Continuada en Atención Primaria
76. Due decadi di storia dei trial con statine tra endpoint clinici, intermedi e surrogati
    Gianna Fabbri, Giuseppe Di Pasquale, Cristiano Greco, Anna Chiara Musuraca, Luigi Tavazzi · 2009 · Giornale italiano di cardiologia
77. Façons d’identifier et de prendre en charge la dyslipidémie athérogène
    N. John Bosomworth · 2013 · Europe PMC (PubMed Central)
78. La riduzione del rischio di nuovi eventi dopo sindrome coronarica acuta: qual è il ruolo delle statine?
    Stefano Urbinati, Graziana Labanti, Simona Gambetti · 2010 · Giornale italiano di cardiologia
79. RISK PREDICTION OF CORONARY ARTERY DISEASE WITH OR WITHOUT DIABETES MELLITUS: APOLIPOPROTEINS SCORE OVER LIPID FRACTIONS.
    Noorjahan Mohammed, Ramarao Janyavula, Bhaskar Raju, Sai Baba, Mallareddy Medial · 2014 · International Journal of Pharma and Bio Sciences
80. Physiological and Clinico- Pharmacological Study of High sensitivity C-reactive protein, as a Prognosis Biomarker in Acute Coronary Syndrome and its Level in AtherostatinTreatment
    Mohammad Reza HafeziAhmadi, Saeed Nafisi, Ehsan Hosseini, Ali Mohammad Bahrami, Someyra Miss Ghavam · 2013
81. Therapeutic Class Overview HMG CoA Reductase Inhibitors
    Lescol Xl · 2012
82. vulnerable plaques: A comparison with a high-dose simvastatin therapy
    Lei Zhang, Yan Liu, Xiao Ting Lu, Yi Ling Wu, Cheng Zhang, Xiao Ping Ji, Rong Wang, Chun Xi Liu, Jin Bo Feng, Hong Jiang et al. · 2009
83. Lipids are vital to life, but are important contributors to pathology.
    Dirk Jacobus Blom · 2009
84. Pharmacy Practice in 2007: An update on hot topics from the hospital to the community
    Kelly Grindrod, Sean P. Spina · 2007
85. Should a Trial with Lost Allocation Key be Incorporated in Meta-analysis?
    Bart G. C. W. Pijls, Boudewijn L. S. Borger van der Burg, Larry Frisch, Anne Jochem Hendrik Vochteloo, Rob G. H. H. Nelissen · 2015 · Journal of Advances in Medicine and Medical Research
86. Estudo randomizado da intervenção coronária percutânea após administração da rosuvastatina para prevenção de infarto do miocárdio periprocedimento
    Kleber Bomfim Araújo Martins · 2014
87. Intensive Statin Therapy Prevents Nonfatal Cardiovascular Events
    Harlan M. Krumholz, Sm · 2006 · Journal watch
88. Statin prescribing in Australian and Irish general practice:a qualitative study
    Brett Montgomery · 2012 · UWA Profiles and Research Repository (University of Western Australia)
89. Dyslipidémies et risque cardiovasculaire : données des études de prévention cardiovasculaire
    Michel Farnier · 2010 · EMC - Endocrinologie - Nutrition
90. From statin efficacy to everyday effectiveness: Studying the gap in between.
    Päivi T. Ruokoniemi · 2015 · UTUPub (University of Turku)
91. FLUXO CORONARIANO, MICROEMBOLIA E OBSTRUÇÃO MICROVASCULAR APÓS TROMBOSE CORONARIANA AGUDA E REPERFUSÃO CORONÁRIA CORONARY FLOW, MICROVASCULAR OBSTRUCTION AND MICROEMBOLIZATION AFTER ACUTE CORONARY THROMBOSIS AND CORONARY REPERFUSION
    Emerson de Albuquerque Seixas · 2010
92. Einfache Therapie fördert die Compliance
    Bernd Mühlbauer · 2012 · CardioVasc
93. New paradigm of treatment with statins in cardiovascular prevention
    Carlo Vigorito, Carmine Chieffo · 2016 · Monaldi Archives for Chest Disease
94. Endothelial dysfunction in patients with glucose abnormalities and coronary artery disease
    Magnus Settergren · 2009
95. The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review
    W Greenheld, Jon Wilson, Susan E Bayliss, Christopher Hyde · 2007
96. Research Highlights
    Simran D. S. Maggo · 2011 · Pharmacogenomics
97. Façons d’identifier et de prendre en charge la dyslipidémie athérogène
    N. John Bosomworth · 2013 · Canadian Family Physician
98. Management of Associated Cardiovascular Risk in Essential Hypertension
    Vasilios Papademetriou · 2008 · Elsevier eBooks
99. A closer look at lipid management following an acute coronary syndrome
    William Edward Moody, Aung Myat · 2011
100. High-Risk Vulnerable Plaques
     Pedro Moreno, Carlos L. Alviar, Javier Sanz, Valentı́n Fuster · 2012 · Elsevier eBooks